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Introduction: Tumor-induced osteomalacia is a paraneoplastic syndrome of hypophosphatemia. Osteomalacia
causes multiple bone fractures and severe pain.
Case presentation: We report the case of a 57-year-old Japanese man with tumor-induced osteomalacia
associated with a middle cranial fossa bone tumor. The tumor was successfully resected by using a middle fossa
epidural approach. His phosphate level recovered to a normal range immediately after the surgery.
Conclusions: It is rare that tumor-induced osteomalacia originates from the middle skull base. This report suggests
that, if patients have a clinical and biochemical picture suggestive of tumor-induced osteomalacia, it is crucial to
perform a meticulous examination to detect the tumor or the lesion responsible for the tumor. The serum level of
fibroblast growth factor 23 is the most reliable marker for evaluating the treatment outcome of tumor-induced
osteomalacia.Introduction
Tumor-induced osteomalacia is a rare acquired disorder.
It has been reported to occur in patients with hypopho-
sphatemia because of excessive renal phosphate excre-
tion secondary to various types of mesenchymal tumors,
including hemangiopericytoma, giant cell tumor, and fi-
broma. Patients typically present with a history of
chronic bone pain, fractures, and proximal motor weak-
ness. Children may exhibit poor growth and lower-
extremity deformity. The tumors are often benign, small,
and difficult to detect. A recent report has suggested
that fibroblast growth factor 23 (FGF-23) is the most re-
liable marker for the detection of these tumors [1].
We report a case of tumor-induced osteomalacia asso-
ciated with a middle fossa bone tumor. The tumor was
successfully resected via a middle fossa epidural approach.
Phosphate level recovered to a normal range immediately
after the surgery. The diagnostic evaluation, etiology of
hypophosphatemia, and treatment are discussed.* Correspondence: chokyui@med.osaka-cu.ac.jp
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A 57-year-old Japanese man was initially referred to our
hospital for treatment of multiple bone fractures. In
2007, he had fallen down and fractured his foot. Fortu-
nately, he had recovered with conservative therapy; how-
ever, the delay of bone fusion in his case was notable. In
2008, he experienced a sudden onset of costal pain with
trivial trauma, and multiple costal fractures were diag-
nosed. The costal pain did not resolve during these two
years. Two years after his initial foot fracture, our patient
exhibited a serum phosphorus concentration of 1.9mL/
dL (normal range is 2.5 to 4.5mg/dL) and a serum cal-
cium concentration of 9.0mg/dL (normal range is 8.5
to 10.5mg/dL). Furthermore, a detailed investigation
revealed persistent hypophosphatemia and a serum 1,25-
dihydroxyvitamin D concentration of 18pg/mL (normal
range is 25 to 50pg/mL). Serum levels of FGF-23 were
elevated to 84pg/mL (normal range is 10 to 50pg/mL).
Subsequent magnetic resonance (MR) images revealed a
tumor in the middle cranial base; the tumor reached the
temporomandibular joint and was 27 × 18 × 20mm in
size. This tumor was clearly and homogeneously
enhanced on gadolinium MR images (Figure 1). Bone
computed tomography scans showed destructive changel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Axial and coronal magnetic resonance images with contrast show a left epidural mass at the middle cranial fossa.
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cranial base (Figure 2). We presumed that hypophospha-
temia and vitamin D deficiency were related to this
tumor.
Two months after the MR images were taken, we per-
formed the tumor resection via a middle fossa epidural
approach. The tumor was located and eroded in the
middle fossa cranial base and was easy to remove by cur-
retting. The tumor had adhered to the dura mater in
some parts but did not invade the subdural space. Fi-
nally, the tumor was totally resected, preserving the tem-
poromandibular joint. Histopathological diagnosis was
consistent with a phosphaturic mesenchymal tumor that
showed round or spindled cells embedded in a smudgy
blue-gray material (Figure 3).
The post-operative course was uneventful. The hypo-
phosphatemia and vitamin D deficiency resolved five days
after the surgery. Serum levels of FGF-23 decreased toFigure 2 Bone computed tomography images demonstrate a bone-ernormal (14pg/mL) seven days after the surgery (Figure 4).
Costal pain in our patient was completely resolved one
month after the surgery. MR images at one-year follow-up
showed no recurrence of the tumor, and his serum phos-
phate level was normal (Figure 5).
Discussion
Tumor-induced osteomalacia is an uncommon condi-
tion. These tumors are usually mesenchymal or mixed
connective tissue arising from either soft tissues or bone
[2]. They are benign in nature. Even in histologically ma-
lignant tumors, local recurrence or distant metastasis is
extremely rare. The most common types of these tumors
are hemangiopericytomas. Other types include fibromas,
chondrosarcomas, neuroblastomas, and prostate carcin-
omas [3,4]. The first case was reported by McCance [5]
in 1947. In 1995, Crouzet and colleagues [6] reviewed
100 cases reported in the medical literature. Since then,oded lesion at the middle cranial fossa.
Figure 3 A photomicrograph of the resected tumor shows small rounded spindled cells with a smudgy matrix (hematoxylin and eosin,
or H-E).
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genic osteomalacia. Gonzalez-Compta and colleagues [7]
reviewed 21 cases of osteomalacia induced by head and
neck tumors. The authors reported that 57% of these


























Figure 4 Charts display pre-and post-operative laboratory dates. OP,
level.mean age at diagnosis was 45 years. There has been no
finding of gender predominance in the previous reports.
Bone pain, muscle weakness, fractures, skeletal deform-
ities, and gait disturbance are the most common clinical





operation. P, phosphorous level. FGF-23, fibroblast growth factor 23
Figure 5 Magnetic resonance images with contrast one year after surgery reveal no enhanced region.
Chokyu et al. Journal of Medical Case Reports 2012, 6:181 Page 4 of 5
http://www.jmedicalcasereports.com/content/6/1/181unusual sites in the body. Pirola and colleagues [8]
reported oncogenic osteomalacia of the thoracic spine.
However, oncogenic osteomalacia originating from the
middle cranial fossa is very rare.
Biochemical analysis often detects abnormalities in
serum chemical concentrations. Generally, those patients
who have hypophosphatemia have normal calcium levels
and a low 1,25-dihydroxyvitamin D concentration. These
imbalances resolve after total surgical exision of the
tumor. The serum phosphate level is basically regulated
by intestinal phosphate absorption, renal phosphate ex-
cretion, and dynamic equilibrium between circulatory
phosphate and intracellular phosphate or phosphate in
calcified bone. Of these, renal phosphate excretion is
believed to be the main regulator of the chronic phos-
phate level. Recently, the mechanism of tumor-induced
osteomalacia was thought to be secondary to inhibition
of the ability of the renal tubule to reabsorb phosphorus
and activate calcitriol synthesis. These processes lead to
hypophosphatemia. The most reliable marker for the de-
tection of tumor-induced osteomalacia is FGF-23 [9],
which is a secreted peptide hormone overexpressed by the
tumor in patients with tumor-induced osteomalacia.
Fukumoto [10] reported that FGF-23 suppresses phos-
phate reabsorption by decreasing expression levels of the
type 2a and 2c sodium phosphate co-transporter in the
brush border membrane of proximal tubules. At the same
time, FGF-23 reduces serum 1,25-dihydroxyvitamin D
levels in part by suppressing 1,25-dihydroxyvitamin
D production. As 1,25-dihydroxyvitamin D enhances in-
testinal phosphate absorption, FGF-23 decreases the
serum phosphate level partly by reducing intestinal phos-
phate absorption through suppressing the serum 1,25-
dihydroxyvitamin D level. Symptoms resolve once the
tumor is totally removed. Therefore, it is necessary to con-
sider the total excision of the tumor as a treatment strategy.Conclusions
We treated a case of hypophosphatemia associated with
tumor-induced osteomalacia. The tumor was success-
fully resected by using a middle fossa epidural approach.
Phosphate levels recovered to normal immediately after
the surgery. For patients who have a clinical and bio-
chemical profile suggestive of tumor-induced osteomal-
acia, it is crucial to perform an in-depth examination to
detect the tumor or the lesion responsible for the tumor.
FGF-23 is the most reliable marker to evaluate the useful-
ness of any treatment for tumor-induced osteomalacia.
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